

## Anti-Human CEACAM5 (Tusamitamab Biosimilar)

<b>Catalog Number:</b>	506501, 506502, 506503
<b>Size:</b>	1 mg, 5 mg, 20 mg
<b>Target Name:</b>	CD66e, CEACAM5, CEA, Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5
<b>Regulatory Status:</b>	RUO

### PRODUCT DETAILS

---

<b>Clone:</b>	Tusamitamab
<b>Application:</b>	Flow cytometry, animal model study
<b>Reactivity:</b>	Human
<b>Format:</b>	Liquid
<b>Product Description:</b>	Tusamitamab Biosimilar, Human CEACAM5 Monoclonal Antibody
<b>Isotype:</b>	Human IgG1
<b>Clonality:</b>	Recombinant
<b>Immunogen:</b>	Human CEACAM5
<b>Species specificity:</b>	Human
<b>Purity:</b>	>95% by reducing SDS-PAGE
<b>Grade:</b>	In vivo
<b>Min Sample Size:</b>	1 mg
<b>Storage Conditions:</b>	4°C
<b>Maximal Shelf Life:</b>	12 months
<b>Synonyms:</b>	CD66e
<b>Antibody Type:</b>	Recombinant
<b>Reactivity:</b>	Human

### BACKGROUND INFORMATION

---

Tusamitamab, as a therapeutic, is an antibody-drug conjugate (ADC) that combines a humanized monoclonal antibody targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) with a potent cytotoxic payload. Structurally, the antibody component belongs to the human immunoglobulin G1 kappa (IgG1 $\kappa$ ) subclass and has a molecular mass of approximately 150 kilodaltons (kDa). It is composed of two identical heavy chains and two identical light chains linked by disulfide bonds in the Y-shaped conformation typical of IgG molecules. The antibody is produced recombinantly in mammalian cell systems, such as Chinese Hamster Ovary (CHO) cells, ensuring proper folding and glycosylation.

The variable regions of the heavy (VH) and light (VL) chains contain complementarity-determining regions (CDRs) that mediate

high-affinity binding to a specific extracellular epitope on CEACAM5, a cell-surface glycoprotein involved in cell adhesion and intercellular signaling. This antigen is largely restricted to certain epithelial lineages, making it an accessible and stable target for molecular binding studies. The antibody's specific recognition enables selective internalization when bound to CEACAM5 at the cell membrane.

The Fc (fragment crystallizable) region of Tusamitamab provides structural stability and extended half-life via neonatal Fc receptor (FcRn) recycling.

This product is supplied subject to the terms and conditions at [www.innocyto.com/web/terms.php](http://www.innocyto.com/web/terms.php) and may only be used as provided in the stated terms. Products are for Research Use Only.